Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics

Takes up the non-executive role at the AI-focused medical imaging firm

Silence Therapeutics' chief executive officer Ali Mortazavi has been appointed non-executive chairman of ultromics - an artificial intelligence-focused medical imaging firm.

Mortazavi has 17 years’ experience in UK companies, particularly in the biotechnology investment field and joined London-based biotech Silence Therapeutics in 2012 leading its refinancing business and driving business.

He said: “I am truly excited to be joining the board of ultromics. Artificial intelligence will increasingly begin to play a bigger role in medicine as well as other sectors. Ultromics plans to use the combination of man plus machine rather than man vs Machine in medical imaging.”

Ultromics - formed in May 2017 - is backed by Oxford Sciences Innovation and the technology has been applied to echocardiograms to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%.

25th July 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...
customer engagement 1
Building meaningful customer engagement through data-driven digital insights
Understanding the helpful insights that online HCP conversations can reveal...

Infographics